康辰藥業(603590.SH)：子公司擬參與優銳開曼E輪融資
格隆匯7月22日丨康辰藥業(603590.SH)公佈，全資子公司康辰藥業（香港）有限公司（簡稱：“康辰香港”）與交易標的優銳開曼及其下屬子公司共同簽署了《SeriesEPreferredSharePurchaseAgreement》（簡稱“《股份認購協議》”），康辰香港擬以15,000萬元人民幣價格，參與優銳開曼E輪融資，認購優銳開曼新發行的38,439,537股E輪優先股。本輪融資募集資金將用於優銳開曼業務拓展、資本支出與營運資金等，以支持其創新藥申報上市，以及滿足其他經營資金需求。
本次交易出資情況爲：優銳開曼下屬子公司優銳生物醫藥（北京）有限公司因現有產品本地化生產向公司租賃廠房等生產設施，租期5年，租金共計7,500本公司董事會及全體董事保證本公告內容不存在任何虛假記載、誤導性陳述或者重大遺漏，並對其內容的真實性、準確性和完整性承擔法律責任。萬元。該租金中的5,000萬元摺合爲康辰香港對優銳開曼的投資款，專項認購優銳開曼新發行的E輪優先股。同時，爲強化雙方的戰略合作，公司以自有資金再行增加投資10,000萬元通過康辰香港認購優銳開曼新發行的E輪優先股（即兩項合計金額15,000萬元人民幣）。本次增資完成後，公司向優銳開曼累計投資金額爲31,203.25萬元人民幣；公司通過康辰香港將持有優銳開曼91,448,871股股份，佔優銳開曼總股本(全面攤薄和轉股基礎上)的比例已超過5%；同時將向優銳開曼指派1名董事，預計將對公司與優銳開曼的後續合作產生積極影響。
優銳開曼設立於開曼羣島，通過全資子公司NuancePharmaLimited及二級全資子公司優銳醫藥科技（上海）有限公司（簡稱“優銳醫藥”）開展實際運營。優銳醫藥是一家以患者爲中心、聚焦創新的生物製藥公司，擁有呼吸類創新研發管線與成熟的商業化產品組合，專注於呼吸系統、缺鐵性貧血等治療領域。其當前重點在研管線恩司芬羣（Ensifentrine），是一款全球首創的吸入型磷酸二酯酶3、4雙靶點抑制劑（PDE3&PDE4），用於維持治療慢性阻塞性肺疾病（COPD）。該藥物憑藉雙重抑制機理，使其能夠憑藉單個化合物同時實現支氣管擴張以及抗炎效應，已於2024年在美國獲批上市（合作夥伴VeronaPharma，納斯達克：VRNA），並獲批落地中國海南博鰲樂城先行區；2025年，該藥在中國澳門特別行政區獲批上市，同年5月在中國大陸COPD三期臨牀試驗中達到主要終點，計劃下半年提交新藥申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
